A Single-Blinded Case-Control Study of Memantine in Severe Obsessive-Compulsive Disorder
The DOI matches its Crossref record; 56 of the 59 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obsessive-compulsive disorder (OCD) is a common debilitating psychiatric illness that typically improves but does not remit with first-line medication and behavioral treatments. Serotonergic agents including selective serotonin reuptake inhibitors and clomipramine have provided the mainstay of OCD medication management for decades. Combined dopamine/serotonergic agents such as atypical antipsychotics are presently the only OCD-augmenting strategies proven effective via randomized controlled trials. Despite increasing evidence for a pathogenic role of glutamate in OCD, no controlled trials of glutamatergic augmenting agents have been reported. METHODS: An intent-to-treat sample included 44 subjects receiving standard treatment at the McLean/Massachusetts General Hospital Intensive Residential Treatment (IRT) program, 22 of whom also received memantine augmentation. Admission, monthly and discharge measures of OCD, depression, and psychosocial functioning were collected by raters blinded to augmentation status. Matched controls were selected based on sex, initial OCD severity, psychosocial functioning, and timing of admission. The Clinical Global Improvement Scale captured global clinical change. RESULTS: Mean (SD) Yale-Brown Obsessive Compulsive Scale score decreases were 7.2 (6.4) among the cases and 4.6 (5.9) among the matched controls, reflecting mean clinical improvement among the cases (27.0% decrease) but not the controls (16.5% decrease). Mean (SD) depression severity score decreases were 5.8 (9.5) among the cases and 4.7 (9.9) among the controls. Initial intrusive obsessions were significantly more severe among marked responders compared with limited response or nonresponse cases (4.4 vs 2.9; t = 2.15; P = 0.048). CONCLUSIONS: This study provides preliminary supportive evidence for the effectiveness of memantine as a glutamatergic augmenting agent in severe OCD. Future randomized double-blind placebo-controlled trials are warranted.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Memantine add-on to fluvoxamine significantly improved short-term outcomes in patients with moderate to severe OCD”
From The neurobiological link between OCD and ADHD (2014) · cites this paper as Stewart et al. 2010
Citations
Cites
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032 · cited 1×
“76, sensitivity of 100%, and specificity of 89% (using a cutoff score of 16).(22,40,41) The Obsessive-Compulsive Rating scale is a questionnaire-based measure that rates the severity of OCD symptom categories between 0 and 10.”
BackgroundThe Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712 · cited 1×
“67)(38) with excellent reliability.(38,39) The Y-BOCS checklist has more than 60 items organized into 2 miscellaneous categories and 13 other categories according to thematic content.”
BackgroundThe Yale-Brown Obsessive Compulsive Scale: II. Validity
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110054008 · Cited by 2,799 · cited 1×
“67)(38) with excellent reliability.(38,39) The Y-BOCS checklist has more than 60 items organized into 2 miscellaneous categories and 13 other categories according to thematic content.”
BackgroundThe Work and Social Adjustment Scale: a simple measure of impairment in functioning
Mundt, J. C., Marks, I. M., Shear, M. K., & Greist, J. M. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.180.5.461 · Cited by 2,515 · cited 1×
“86, and increasing scores that reflect worse functional impairment.(43) The Clinical Global Impression (CGI) scale provides an assessment of overall impact of treatment rated between 1 (very much improved) and 7 (very much worse).”
BackgroundThe Yale-Brown Obsessive-Compulsive Scale: Measures of internal consistency
Kim, S. W., Dysken, M. W., Pheley, A. M., & Hoover, K. M. (1994) · Psychiatry Research · doi:10.1016/0165-1781(94)90039-6 · Cited by 2,359
The Epidemiology of Obsessive-Compulsive Disorder in Five US Communities
Karno, M. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800360042006 · Cited by 1,351
Foa, E. B., Liebowitz, M. R., Kozak, M. J., Davies, S., Campeas, R., Franklin, M. E., Huppert, J. D., Kjernisted, K., Rowan, V., Schmidt, A. B., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.151 · Cited by 1,048 · cited 1×
“First-line OCD treatments, including selective serotonin reuptake inhibitors (SSRIs), cognitivebehavior therapy (CBT), and their combination, are effective in approximately 42% to 50%,(3) 62%, and 70% of cases, respectively.(4) However, symptoms often persist and full remission is uncommon with first-line approaches.”
BackgroundCortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice
Welch, J. M., Lu, J., Rodriguiz, R. M., Trotta, N. C., Peca, J., Ding, J.-D., Feliciano, C., Chen, M., Adams, J. P., Luo, J., et al. (2007) · Nature · doi:10.1038/nature06104 · Cited by 852 · cited 1×
“Knockout mice for the striatum-expressed SAPAP3 gene, coding for a postsynaptic scaffolding protein at corticostriatal glutamatergic excitatory synapses, also developed facial lesions, repetitive grooming behaviors, and anxiety that were reversed with an SSRI and with gene replacement.(33) Memantine is a glutamate rec…”
BackgroundSynopsis of Psychiatry: 5th edn. Behavioral Sciences Clinical Psychiatry
Kaplan, H. I., & Sadock, B. J. (1989) · International Clinical Psychopharmacology · doi:10.1097/00004850-198907000-00008 · Cited by 852
Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder
Saxena, S., & Rauch, S. L. (2000) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70181-7 · Cited by 840 · cited 1×
“24 Moreover, glutamate receptor antagonism leads to an enhancement of 5-HT2A receptorYmediated transmission; 5-HT2A agonism leads to reduced glutamatergic transmission(24) and 5-HT receptor activation reduces the excitatory effect of glutamate on cellular activity.(50) It is this interaction that is believed to contri…”
Background
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Adjunctive lamotrigine [799,800] 2 Adjunctive memantine [622,781-783] 2”
BackgroundBaldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
“…obsessive-compulsive disorder include monotherapy with once-weekly morphine [I (PCT)] (Koran et al., 2005); and the glutamate-modulating compounds riluzole [III] (Coric et al., 2005; Pittenger et al., 2008), memantine [III] (Stewart et al., 2010), and glycine [I (PCT)(Greenberg et al., 2009).”
BackgroundPittenger, C., Bloch, M. H., & Williams, K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.006 · Cited by 426
“…below, genetic studies have suggested an association between polymorphisms in the NMDA NR2B subunit and OCD risk (Arnold et al., 2004), and early pharmacological studies with the NMDA-blocking drug memantine have shown promise (Aboujaoude et al., 2009; Feusner et al., 2009; Stewart et al., 2010).”
BackgroundRandomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., & Simpson, H. B. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.150 · Cited by 386
“…and memantine) have been shown to ameliorate OCD symptoms in open (Aboujaoude et al , 2009; Coric et al , 2005; Feusner et al , 2009; Lafleur et al , 2006; Pittenger et al , 2011; Rodriguez et al , 2010; Stewart et al , 2010) and controlled trials (Afshar et al , 2012; Ghaleiha et al , 2013).”
Evidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder
Goodman, W. K., Storch, E. A., & Sheth, S. A. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20111601 · Cited by 250
Sani, G., Serra, G., Kotzalidis, G. D., Romano, S., Tamorri, S. M., Manfredi, G., Caloro, M., Telesforo, C. L., Caltagirone, S. S., Panaccione, I., et al. (2012) · CNS Drugs · doi:10.2165/11634390-000000000-00000 · Cited by 273
The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder
Wu, K., Hanna, G. L., Rosenberg, D. R., & Arnold, P. D. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.10.007 · Cited by 264
“Recently, a single blind, case-control study reported memantine was an effective augmenting agent to standard Intensive Residential Treatment (IRT) in severe OCD (Stewart et al., 2010).”
Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD)
Del Casale, A., Sorice, S., Padovano, A., Simmaco, M., Ferracuti, S., Lamis, D. A., Rapinesi, C., Sani, G., Girardi, P., Kotzalidis, G. D., et al. (2019) · Current Neuropharmacology · doi:10.2174/1570159x16666180813155017 · Cited by 223
Pharmacological Treatment of Obsessive-Compulsive Disorder
Pittenger, C., & Bloch, M. H. (2014) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2014.05.006 · Cited by 222
Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000740 · Cited by 211
New perspectives in glutamate and anxiety
Riaza Bermudo-Soriano, C., Perez-Rodriguez, M. M., Vaquero-Lorenzo, C., & Baca-Garcia, E. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.04.010 · Cited by 207
“A recent single-blinded case–control study (Stewart et al., 2010), evaluating the efficacy of memantine augmentation treatment in patients suffering severe OCD, found a significant decrease in the Yale-Brown Obsessive Compulsive Scale score among patients receiving memantine adjunctive therapy.”
Effects of Ketamine in Treatment-Refractory Obsessive-Compulsive Disorder
Bloch, M. H., Wasylink, S., Landeros-Weisenberger, A., Panza, K. E., Billingslea, E., Leckman, J. F., Krystal, J. H., Bhagwagar, Z., Sanacora, G., & Pittenger, C. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.028 · Cited by 162
Fineberg, N. A., Hollander, E., Pallanti, S., Walitza, S., Grünblatt, E., Dell’Osso, B. M., Albert, U., Geller, D. A., Brakoulias, V., Janardhan Reddy, Y. C., et al. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000314 · Cited by 161
“There may also be difficulty detecting the disorder in childhood (Storch et al., 2014).”
BackgroundGhaleiha, A., Entezari, N., Modabbernia, A., Najand, B., Askari, N., Tabrizi, M., Ashrafi, M., Hajiaghaee, R., & Akhondzadeh, S. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.09.015 · Cited by 152
Pharmacotherapy of anxiety disorders: A critical review
Koen, N., & Stein, D. J. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.4/nkoen · Cited by 151
“The serendipitous discovery that clomipramine (CMI), a more serotonergic tricyclic, is effective for obsessivecompulsive disorder (OCD) was important in giving impetus to a serotonin hypothesis of OCD.47 Subsequent work found that the more selective SSRIs were not only efficacious but also well-tolerated.48 More recen…”
InfluentialPharmacotherapy of obsessive–compulsive disorder: evidence-based treatment and beyond
Fineberg, N. A., Reghunandanan, S., Brown, A., & Pampaloni, I. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412461958 · Cited by 122
Pharmacological Management of Treatment-Resistant Obsessive-Compulsive Disorder
Abudy, A., Juven‐Wetzler, A., & Zohar, J. (2011) · CNS Drugs · doi:10.2165/11587860-000000000-00000 · Cited by 119
“6 among the control patients receiving standard treatment.([76]) Another study compared the efficacy of memantine in OCD and generalized anxiety disorder.”
Haghighi, M., Jahangard, L., Mohammad-Beigi, H., Bajoghli, H., Hafezian, H., Rahimi, A., Afshar, H., Holsboer‐Trachsler, E., & Brand, S. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3067-z · Cited by 121
“…a single-blind case–control study to exploring the influence of memantine augmentation in 38 out-patients suffering from OCD; to our knowledge, Stewart et al. (2010) were among the first to demonstrate the symptom improving effects of memantine augmentations in patients suffering from…”
BackgroundMethodResultInfluentialMurphy, D. L., Moya, P. R., Fox, M. A., Rubenstein, L. M., Wendland, J. R., & Timpano, K. R. (2013) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2012.0435 · Cited by 106
“in case studies [98–100], in open-label studies [101,102] and in a case–control study [103].”
BackgroundResultThe neurobiological link between OCD and ADHD
Brem, S., Grünblatt, E., Drechsler, R., Riederer, P., & Walitza, S. (2014) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-014-0146-x · Cited by 109
“Memantine add-on to fluvoxamine signifi- cantly improved short-term outcomes in patients with moderate to severe OCD (Ghaleiha et al. 2013; Hezel et al. 2009; Stewart et al. 2010).”
BackgroundAssessment and Management of Treatment-Refractory Obsessive-Compulsive Disorder in Children
Bloch, M. H., & Storch, E. A. (2015) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2015.01.011 · Cited by 104
Stewart, S. E., Mayerfeld, C., Arnold, P. D., Crane, J. R., O'Dushlaine, C., Fagerness, J. A., Yu, D., Scharf, J. M., Chan, E., Kassam, F., et al. (2013) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32137 · Cited by 102
“Multiple studies have reported symptom improvement in OCD by augmenting with glutamatemodulating agents such as riluzole [Coric et al., 2005; Grant et al., 2007] or memantine [Aboujaoude et al., 2009; Stewart et al., 2010].”
BackgroundSelf-citationTreatment-resistant OCD: Pharmacotherapies in adults
van Roessel, P. J., Grassi, G., Aboujaoude, E. N., Menchón, J. M., Van Ameringen, M., & Rodríguez, C. I. (2023) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2022.152352 · Cited by 86
Harvey, B. H., & Shahid, M. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.06.014 · Cited by 97
Obsessive-compulsive disorder: Insights from animal models
Szechtman, H., Ahmari, S. E., Beninger, R. J., Eilam, D., Harvey, B. H., Edemann-Callesen, H., & Winter, C. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.04.019 · Cited by 97
History of Psychosurgery: A Psychiatrist's Perspective
Lapidus, K. A. B., Kopell, B. H., Ben‐Haim, S., Rezai, A. R., & Goodman, W. K. (2013) · World Neurosurgery · doi:10.1016/j.wneu.2013.02.053 · Cited by 97
Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder
Marinova, Z., Chuang, D.-M., & Fineberg, N. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170320104237 · Cited by 83
“In a further single-blind case-control study of 44 adult patients with severe, treatment-resistant OCD 22 received memantine augmentation to their treatment regimen [86], while 22 served as controls.”
BackgroundMethodPittenger, C., Bloch, M. H., Wasylink, S., Billingslea, E., Simpson, R., Jakubovski, E., Kelmendi, B., Sanacora, G., & Coric, V. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09123 · Cited by 80
Rossignol, D. A., & Frye, R. E. (2014) · Frontiers in Pediatrics · doi:10.3389/fped.2014.00087 · Cited by 79
“Memantine has been reported to help obsessive–compulsive disorder (OCD) as well as impulsive behaviors in open-label (44–48), single blind (49), and placebo-controlled studies (50, 51).”
BackgroundInvestigating the Role of Glutamate in Obsessive-Compulsive Disorder: Current Perspectives
Karthik, S., Sharma, L. P., & Narayanaswamy, J. C. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s211703 · Cited by 88
Augmentation strategies in obsessive–compulsive disorder
Arumugham, S. S., & Reddy, J. Y. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.160 · Cited by 75
Haghighi, M., Shayganfard, M., Jahangard, L., Ahmadpanah, M., Bajoghli, H., Pirdehghan, A., Holsboer‐Trachsler, E., & Brand, S. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.06.020 · Cited by 83
Treatment of Pediatric Obsessive-Compulsive Disorder: A Review
Mancuso, E., Faro, A. L., Joshi, G., & GELLER, D. A. (2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0040 · Cited by 74
“However, only 36% of case patients were found to be responders (Stewart et al. 2010), raising the possibility of a subtype of OCD for which this approach is beneficial.”
A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder
Stein, D. J., Koen, N., Fineberg, N., Fontenelle, L. F., Matsunaga, H., Osser, D., & Simpson, H. B. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0268-9 · Cited by 65
Esalatmanesh, S., Abrishami, Z., Zeinoddini, A., Rahiminejad, F., Sadeghi, M., Najarzadegan, M., Shalbafan, M., & Akhondzadeh, S. (2016) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12430 · Cited by 71
“Generally, it has an early age onset during childhood or early adult life.1–3 The course of illness is waxing and waning chronically if left untreated.4,5 OCD severely impairs quality of life in patients.6 Cognitive-behavioral therapy in the form of exposure and response prevention (ERP) and medication management are…”
BackgroundInfluentialModarresi, A., Chaibakhsh, S., Koulaeinejad, N., & Koupaei, S. R. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.112602 · Cited by 61
Glutamatergic agents for OCD and related disorders
Pittenger, C. (2015) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-015-0051-8 · Cited by 62
Rodriguez, C. I., Kegeles, L. S., Flood, P., & Simpson, H. B. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10l06653 · Cited by 59
Emamzadehfard, S., Kamaloo, A., Paydary, K., Ahmadipour, A., Zeinoddini, A., Ghaleiha, A., Mohammadinejad, P., Zeinoddini, A., & Akhondzadeh, S. (2016) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12394 · Cited by 55
Modarresi, A., Sayyah, M., Razooghi, S., Eslami, K., Javadi, M., & Kouti, L. (2017) · Pharmacopsychiatry · doi:10.1055/s-0043-120268 · Cited by 62
“The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) is commonly used in clinical studies to assess the severity of OCD and response to treatment [25, 26, 31].”
MethodMinocycline Augmentation of Pharmacotherapy in Obsessive-Compulsive Disorder: An Open-Label Trial
Rodriguez, C. I., Bender, J., Marcus, S. M., Snape, M., Rynn, M., & Simpson, H. B. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09l05805blu · Cited by 56
Pharmacotherapeutic Strategies and New Targets in OCD
Pittenger, C. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2020_204 · Cited by 58
Glutamate drugs and pharmacogenetics of OCD: a pathway-based exploratory approach
Grados, M. A., Specht, M. W., Sung, H.-M., & Fortune, D. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.845553 · Cited by 49
“The augmentation group showed a mean clinical improvement of 27% compared to a 17% decrease in the nonaugmented group, providing preliminary support for the use of memantine in severe OCD [115].”
ResultHeidari, M., Zarei, M., Hosseini, S. M. R., Taghvaei, R., Maleki, H., Tabrizi, M., Fallah, J., & Akhondzadeh, S. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000043 · Cited by 48
“Furthermore, on the basis of the glutamatergic hypothesis of OCD, different studies have shown augmentative properties for glutamate NMDA-receptor-modulating agents (Poyurovsky et al., 2005; Pasquini and Biondi, 2006; Kushner et al., 2007; Wilhelm et al., 2008; Aboujaoude et al., 2009; Feusner et al., 2009; Hezel et a…”
BackgroundLee, D. K., & Lipner, S. R. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19116370 · Cited by 47
Brain structural abnormalities in Doberman pinschers with canine compulsive disorder
Ogata, N., Gillis, T. E., Liu, X., Cunningham, S. M., Lowen, S. B., Adams, B. L., Sutherland‐Smith, J., Mintzopoulos, D., Janes, A. C., Dodman, N. H., et al. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.04.002 · Cited by 51
“Further, it has been shown that humans with OCD (Aboujaoude et al., 2009; Feusner et al., 2009; Stewart et al., 2010) and dogs with CCD respond to treatment with the glutamatergic NMDA receptor antagonist memantine (Schneider et al., 2009).”
Self-citationMemantine: a review of possible uses in child and adolescent psychiatry.
Hosenbocus, S., & Chahal, R. (2013) · Europe PMC (PubMed Central) · Cited by 64
Advances in pharmacotherapy for pediatric anxiety disorders
Rynn, M., Puliafico, A., Heleniak, C., Rikhi, P., Ghalib, K., & Vidair, H. (2011) · Depression and Anxiety · doi:10.1002/da.20769 · Cited by 44
Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder
Grassi, G., Cecchelli, C., Vignozzi, L., & Pacini, S. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s255375 · Cited by 44
Memantine and Catatonia: A Case Report and Literature Review
Obregon, D. F., Velasco, R. M., Wuerz, T. P., Catalano, M. C., Catalano, G., & Kahn, D. A. (2011) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000400268.60537.5e · Cited by 50
Sarcosine Therapy for Obsessive Compulsive Disorder: A Prospective, Open-Label Study
Wu, P.-L., Tang, H.-S., Lane, H.-Y., Tsai, C.-A., & Tsai, G. E. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182189878 · Cited by 40
“For example, Rosenberg et al4 have reported reduced glutamatergic concentrations in the anterior cingulate gyrus in drug-naive pediatric patients with OCD.”
BackgroundInfluentialAfshar, H., Akuchekian, S., Mahaky, B., & Zarean, E. (2014) · PubMed Central · Cited by 51
The Use of Memantine in Neuropsychiatric Disorders: An Overview
Lu, S., & Nasrallah, H. A. (2018) · Annals of Clinical Psychiatry · doi:10.1177/104012371803000307 · Cited by 45
Porton, B., Greenberg, B. D., Askland, K., Serra, L. M., Gesmonde, J., Rudnick, G., Rasmussen, S. A., & Kao, H.-T. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.35 · Cited by 36
Khalkhali, M., Aram, S., Zarrabi, H., Kafie, M., & Heidarzadeh, A. (2016) · PubMed Central · Cited by 36
Memantine for autism spectrum disorder
Brignell, A., Marraffa, C., Williams, K. J., & May, T. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013845.pub2 · Cited by 46
Arabzadeh, S., Shahhossenie, M., Mesgarpour, B., Rezaei, F., Shalbafan, M., Ghiasi, Z., & Akhondzadeh, S. (2017) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2584 · Cited by 39
“Memantin has been used in patients with treatment resistant OCD (Aboujaoude, Barry, & Gamel, 2009; Bakhla, Verma, Soren, et al., 2013; Haghighi, Jahangard, Mohammad‐Beigi, et al., 2013; Stewart et al., 2010) and also as an adjuvant in moderate to severe OCD (Ghaleiha et al.”
MethodThe Glutamate Hypothesis: A Pathogenic Pathway from which Pharmacological Interventions have Emerged
Veerman, S. R. T., Schulte, P. F. J., & de Haan, L. (2014) · Pharmacopsychiatry · doi:10.1055/s-0034-1383657 · Cited by 38
Askari, S., Mokhtari, S., Shariat, S. V., Shariati, B., Yarahmadi, M., & Shalbafan, M. (2022) · BMC Psychiatry · doi:10.1186/s12888-021-03642-z · Cited by 35
“Open-label studies [51], single [52] and double-blind randomized controlled trials (RCTs) [53, 54] and one systematic review and meta-analysis [55] showed benefits of adding memantine to ongoing SSRI in the treatment of OCD.”
BackgroundN-Acetyl-L-Cysteine Inhibits Marble-Burying Behavior in Mice
Egashira, N., Shirakawa, A., Abe, M., Niki, T., Mishima, K., Iwasaki, K., Oishi, R., & Fujiwara, M. (2012) · Journal of Pharmacological Sciences · doi:10.1254/jphs.11228sc · Cited by 32
An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder
Chaudhury, S., Bakhla, A. K., Verma, V. K., Soren, S., & Sarkhel, S. (2013) · Industrial Psychiatry Journal · doi:10.4103/0972-6748.132930 · Cited by 32
“[5] Although the duration of 12 weeks was the same as of our study, previous studies used higher dose (20 mg/day) of memantine in comparison to 10 mg/day in our study [Table 3].”
Häge, A., Banaschewski, T., Buitelaar, J. K., Dijkhuizen, R. M., Franke, B., Lythgoe, D. J., Mechler, K., Williams, S., & Dittmann, R. (2016) · Trials · doi:10.1186/s13063-016-1266-8 · Cited by 33
Role of Glutamatergic System in Obsessive-Compulsive Disorder with Possible Therapeutic Implications
Vlček, P., Polák, J., Brunovský, M., & Horáček, J. (2017) · Pharmacopsychiatry · doi:10.1055/s-0043-118665 · Cited by 33
Treatment of obsessive-compulsive disorders (OCD) and obsessive-compulsive-related disorders (OCRD)
Krzyszkowiak, W., Kuleta-Krzyszkowiak, M., & Krzanowska, E. (2019) · Psychiatria Polska · doi:10.12740/pp/105130 · Cited by 28
Current and up-and-coming pharmacotherapy for obsessive-compulsive disorder in adults
Grassi, G., & Pallanti, S. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1528230 · Cited by 29
Mowla, A., & Ghaedsharaf, M. (2019) · CNS Spectrums · doi:10.1017/s1092852919001500 · Cited by 27
“Riluzole and memantine are glutamate antagonists that have been found to be effective in the treatment ofOCDpatients.(19,21,32)Othermedicationwith glutamatemodulating properties that have shown anti-OCD efficacy are lamotrigine, topiramate, amantadine, ketamine, glycine, and D-cycloserine.”
BackgroundFarnia, V., Gharehbaghi, H., Alikhani, M., Almasi, A., Golshani, S., Tatari, F., Davarinejad, O., Salemi, S., Bahmani, D. S., Holsboer‐Trachsler, E., et al. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.07.008 · Cited by 27
Prados-Pardo, Á., Martín-González, E., Mora, S., Merchán, A., Flores, P., & Moreno, M. (2019) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2019.00100 · Cited by 26
Clinical Pharmacology of Comorbid Obsessive–Compulsive Disorder in Tourette Syndrome
Neri, V., & Cardona, F. (2013) · International review of neurobiology · doi:10.1016/b978-0-12-411546-0.00013-5 · Cited by 25
N-acetylcysteine augmentation in treatment resistant obsessive compulsive disorder: A case series
Ameringen, M. V., Patterson, B. A., Simpson, W. S., & Turna, J. (2012) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2012.10.003 · Cited by 25
Emerging drugs to treat obsessive–compulsive disorder
Pallanti, S., Grassi, G., & Cantisani, A. (2013) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.875157 · Cited by 26
Pittenger, C., Brennan, B. P., Koran, L. M., Mathews, C. A., Nestadt, G., Pato, M. T., Phillips, K. A., Rodríguez, C. I., Simpson, H. B., Skapinakis, P., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113853 · Cited by 24
The Genetics of Obsessive-Compulsive Disorder
Stewart, S. E., & Pauls, D. L. (2010) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.8.3.foc350 · Cited by 25
Self-citationRodriguez, C. I., Levinson, A., Zwerling, J., Vermes, D., & Simpson, H. B. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15l10318 · Cited by 22
Real, E., Gratacòs, M., Labad, J., Alonso, P., Escaramís, G., Segalàs, C., Subirà, M., López‐Solà, C., Estivill, X., & Menchón, J. M. (2012) · The Pharmacogenomics Journal · doi:10.1038/tpj.2012.30 · Cited by 22
Wolmarans, D. W., Stein, D. J., & Harvey, B. H. (2016) · Social Neuroscience · doi:10.1080/17470919.2016.1145594 · Cited by 21
“symptom severity and treatment resistance (Alarcon, Libb, & Spitler, 1993; Khanna, Rajendra, & Channabasavanna, 1988) with a poor treatment outcome (Stewart et al., 2010).”
BackgroundGlutamate-based anxiolytic ligands in clinical trials
Wierońska, J. M., & Pilc, A. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.803066 · Cited by 25
“…of symptoms in half of the subjects Aboujaoude et al. 2009 [63] NCT00869505 n/a OCD 22 subjects Improvement (27% decrease of symptoms) Stewart et al. 2010 [64] NCT00674219 Phase III OCD, GAD 10 OCD, 7GAD/ 10 mg/day/12 weeks Improvement in OCD patients Feusner et al. 2009 [65]…”
BackgroundResultInfluentialRecent advances in the treatment of anxiety disorders.
Antony, M. M. (2011) · Canadian Psychology/Psychologie canadienne · doi:10.1037/a0022237 · Cited by 23
Treatment Resistance in Obsessive-Compulsive Disorder
Middleton, R., Wheaton, M. G., Kayser, R., & Simpson, H. B. (2019) · Treatment Resistance in Psychiatry · doi:10.1007/978-981-10-4358-1_11 · Cited by 19
Obsessive-Compulsive Disorder: Diagnosis, Epidemiology, Etiology, and Treatment
Sassano-Higgins, S. A., & Pato, M. T. (2015) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.130211 · Cited by 26
The Glutamate and the Immune Systems: New Targets for the Pharmacological Treatment of OCD
Marazziti, D., Albert, U., Mucci, F., & Piccinni, A. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867324666171108152035 · Cited by 20
The NMDA receptor antagonists memantine and ketamine as anti-migraine agents
Podkowa, K., Czarnacki, K., Borończyk, A., Borończyk, M., & Paprocka, J. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02444-2 · Cited by 21
Management of obsessive-compulsive disorder comorbid with bipolar disorder
Kazhungil, F., & Mohandas, E. (2016) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.192001 · Cited by 19
“[55] In a single-blind, case-control study of add-on memantine (5 mg/day–18 mg/day) in 22 severe OCD patients receiving standard intensive residential treatment (IRT) with both CBT and drug treatment,[110] memantine group showed significantly more improvement than IRT group and no drug group.”
BackgroundSharma, M., Zibly, Z., Deogaonkar, M. S., & Rezai, A. R. (2016) · Springer eBooks · doi:10.1007/978-1-4939-2528-5_38 · Cited by 40
Ramakrishnan, D. S., Farhat, L. C., Vattimo, E. F. D. Q., Levine, J. L. S., Johnson, J. A., Artukoglu, B. B., Landeros‐Weisenberger, A., Zangen, A., Pélissolo, A., Pereira, C. A. D. B., et al. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.03.044 · Cited by 17
Treatment of pediatric anxiety disorders
Rapp, A. M., Dodds, A., Walkup, J. T., & Rynn, M. A. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12318 · Cited by 19
Bakhla, A. K., Gore, P., & Srivastava, S. (2013) · Industrial Psychiatry Journal · doi:10.4103/0972-6748.123636 · Cited by 16
Advances in the management of treatment-resistant anxiety disorders
Lanouette, N. M., & Stein, M. B. (2010) · Focus · doi:10.1176/foc.8.4.foc501 · Cited by 15
Gattuso, J. J., Wilson, C., Hannan, A. J., & Renoir, T. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109689 · Cited by 14
Pharmacotherapy for obsessive—compulsive disorder
Fineberg, N. A., & Brown, A. (2011) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.109.007237 · Cited by 15
Psychotherapeutische und medikamentöse Behandlung der kindlichen Zwangsstörung
Vloet, T. D., Simons, M., & Herpertz‐Dahlmann, B. (2011) · Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie · doi:10.1024/1422-4917/a000147 · Cited by 15
Katzman, M. A., Bleau, P., Blier, P., Chokka, P. R., Kjernisted, K. D., & Ameringen, M. V. (2021) · doi:10.32920/14638581 · Cited by 13
Murphy, T. K., Frazier, S., & Kim, S. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-252-6_10 · Cited by 12
Brakoulias, V., & Tsalamanios, E. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1250886 · Cited by 13
“One study [15] reported that there were more sexual, aggressive, and religious obsessions in responders of a memantine augmentation trial.”
BackgroundBiological treatments for obsessive-compulsive and related disorders
Borue, X., Sharma, M., & Hudak, R. (2015) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2015.03.003 · Cited by 12
Cycloserine Induced-Psychosis in a 22-Year Old Male Pharmacy Student: A Case Report
Nkporbu, A. K., Oluwaseun, A., Denis, A. D., & Chukwuemeka, S. P. (2016) · American Journal of Psychiatry and Neuroscience · doi:10.11648/j.ajpn.20160401.11 · Cited by 10
“The role of NMDAR and glutamate-modulating agents such as D-cycloserine, riluzole, ketamine, and memantine is now being explored in resistant depression, mood disorders, and obsessive compulsive disorders [19, 20, 21].”
BackgroundLate Onset Neutropenia Associated With Clozapine
Raja, M., Azzoni, A., & Maisto, G. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318234eec2 · Cited by 11
Ferguson, A. A., Khan, A. I., Abuzainah, B., Chaudhuri, D., Khan, K. I., Shouli, R. A., Allakky, A., & Hamdan, J. A. (2023) · Cureus · doi:10.7759/cureus.37833 · Cited by 15
Evidence-Based Pharmacotherapy for Pediatric Obsessive-Compulsive Disorder and Chronic Tic Disorders
Nadai, A. S. D., Storch, E. A., Mcguire, J. F., Lewin, A. B., & Murphy, T. K. (2011) · Journal of Central Nervous System Disease · doi:10.4137/jcnsd.s6616 · Cited by 10
Metadata
- Authors
- Stewart, S. E., Jenike, E. A., Hezel, D. M., Stack, D. E., Dodman, N. H., Shuster, L., & Jenike, M. A.
- Affiliations
- Harvard University (US)
- McLean Hospital (US)
- Tufts University (US)
- Corresponding author
- Stewart, S. Evelyn
- Jenike, Eric A.
- Hezel, Dianne M.
- Stack, Denise Egan
- Jenike, Michael A.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2010-02
- Volume
- 30
- Issue
- 1
- Pages
- 34-39
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2056828397
- Cited by
- 158
- References
- 59
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 8 · 2023: 4 · 2022: 7 · 2021: 9 · 2020: 2 · 2019: 9 · 2018: 6 · 2017: 7 · 2016: 15 · 2015: 11 · 2014: 13 · 2013: 18 · 2012: 14
- FWCI
- 21.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- memantine, obsessive-compulsive disorder, drug augmentation, depression severity, Yale-Brown Obsessive Compulsive Scale, treatment response
- MeSH terms
- Adult, Benzodiazepines, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Inpatients, Male, Memantine, Obsessive-Compulsive Disorder, Residential Facilities, Antipsychotic Agents, Case-Control Studies, Single-Blind Method, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Excitatory Amino Acid Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.